Partnerships and Community
Gilead is dedicated to developing innovative medicines for life-threatening illnesses – and we recognise that it takes more than medicine to address challenges people and communities face.
That’s why we work with organisations around the world to launch programs that help improve access to care by eliminating barriers and advancing education.
Our Partnerships in Australia and New Zealand
In Australia and New Zealand, Gilead invests in partnerships that share our beliefs and our commitment to creating a healthier world.
Whether it's with patient organisations, healthcare professionals, or industry, we aim to build relationships that will help bring lasting improvements to people's care.
We work closely with patients and patient groups to understand their experiences, advocate for their priorities and enable their voices to be heard.
Gilead forms collaborative working initiatives with the healthcare sector, that creates long-term improvements in care for the benefit of people with life-threatening diseases.
In Australia, our annual Community Grants Program currently provides up to AUD$260,000 each year to support community-led programs and activities across our therapeutic areas of HIV, liver disease, blood and metastatic breast cancer. Learn more about our corporate giving
We also fund projects that support communities which have systematically experienced greater social or economic obstacles to health. And we help community organisations that promote wellbeing in our local neighbourhoods and cities.
HIV Community Support
Gilead is a leading philanthropic supporter of initiatives addressing HIV and is steadfastly commited to advancing health equity in the communities we serve.
In Australia, we support the HIV community in various ways, including:
- Providing grants and sponsorships to community and academic centres to drive innovation in HIV prevention and treatment strategies, champion policies that address discrimination and eliminate barriers to care.
- In 2022 alone, we donated more than AUD$1M to support Australian HIV community-led projects through our global ‘Zeroing In Grant’ in support of reducing HIV infections to zero.
- This included a grant to NAPWHA, together with 14 state and territory community groups and clinical and academic partners to increase timely HIV diagnosis, reduce the prevalence of people with undiagnosed HIV and reduce new infections through self-testing, resulting in the creation of https://hivtest.au/. You can find out more about this project here
- The annual Community Champions program, we co-created with NAPWHA, that recognises the unsung heroes of the Australia’s HIV response.
Learn more about the Community Champions.
- Our Young Emerging Scientists (YES) HIV Fellowships, launched in 2023, in collaboration with some of Australia’s preeminent HIV research centres to inspire the next generation of Australian scientists to pursue the elimination of HIV.
Towards elimination of Hepatitis C by 2030
We are committed to working in partnership with the hepatitis sector to help Australia achieve the World Health Organization’s goal of eliminating Hepatitis C (HCV) as a public health threat by 2030. Over the past eight years in Australia, we have invested over AU$15M+ in collaborations with local clinical associations, researchers and patient advocacy groups to support HCV elimination.
In 2023, we donated over AU$400,000 to Australian community organisations as part of the All4 Liver Grant.
Supporting Health Equity in partnership with Our Indigenous Communities
In 2024, Gilead launched the inaugural GLOWS Indigenous Health Program Grant, a US$3M investment over three years, to support health equity in HIV and viral hepatitis. The Program is delivered in partnership with the Lowitja Institute and with support from the Poche Centre for Indigenous Health at the University of Queensland. [GLOWS Infographic loaded as an attachment].
Find out more here https://www.lowitja.org.au/research/funding-opportunities/glows-grant-program-scholarships/
Commitment to Reconciliation
Gilead Australia is proud to be on our reconciliation journey. We have completed our REFLECT Reconciliation Action Plan (RAP) and will soon launch our INNOVATE RAP. You can read our REFLECT RAP here.
Fuelling Local Research and Development
Since 2015, Gilead has provided more than AUD$8 in funding for Australia and New Zealand-led medical education and independent scientific research.
We are a top 10 clinical trial sponsor, dedicated to advancing research in HIV, liver diseases, inflammatory conditions, emerging viruses, oncology and cell therapy, with many active and planned Phase 1 - 3 trials in these therapeutic areas in Australia and New Zealand.
Learn more about clinical trials in Australia and New Zealand
Gilead supports numerous patient advocacy and community groups and medical education activities each year. From Grant funding, to sponsorships and collaborations, Gilead works with organisations across Australia and New Zealand – in areas including viral hepatitis, blood cancer and breast cancer – to help improve access to information and ultimately improve patient outcomes.
For more information please email [email protected].